fgfr 4

FGFR-IN-4 is a potent inhibitor of FGFR. FGFR-IN-4 has potential for cancer disease studies.

FGFR4-IN-16 (CY-15-2) is a covalent inhibitor targeting FGFR-4, utilized in cancer research [1].

FGFR4-IN-1 is a potent FGFR4 inhibitor (IC50: 0.7 nM).

FGFR4-IN-5, a covalent FGFR4 inhibitor, demonstrates potency and selectivity with an IC50 value of 6.5 nM. Exhibiting significant in vivo anti-tumor activity, it is applicable for research in hepatocellular carcinoma [1].

FGFR4-IN-7 is a covalent, reversible FGFR4 inhibitor (IC50: 0.42 μM) that blocks the FGFR4 signaling pathway, thereby inducing apoptosis.

FGFR3-IN-4 is a selective inhibitor targeting FGFR3, demonstrating an IC50 value of under 50 nM. This compound exhibits at least a tenfold greater selectivity for FGFR3 compared to FGFR1.

FGFR4-IN-14 (Compound 27i) is a selective FGFR4 inhibitor with an IC50 of 2.4 nM, showing potent inhibition of cell proliferation in the V550L and N535K mutant strains. Specifically, it registers IC50 values of 21 nM against Huh7 cells, 2.5 nM against BaF3/ETV6-FGFR4-V550L cells, and 171 nM against BaF3/ETV6-FGFR4-N535K cells. Demonstrating significant antitumor efficacy in the Huh7 xenograft model, FGFR4-IN-14 is utilized in the research of hepatocellular carcinoma (HCC) [1].

FGFR4-IN-10 (compound 5a) is a selective and potent inhibitor of FGFR4 (IC50: 70.7 nM).FGFR4-IN-10 does not inhibit other FGFR family members (i.e., FGFR1, FGFR2, and FGFR3).

FGFR4-IN-9 is a selective inhibitor of FGFR4 (IC50: 75.3 nM) that effectively inhibits the growth and angiogenesis of hepatocellular carcinoma cells.

FGFR4-IN-11 is a selective, potent, covalently bound FGFR4 inhibitor (IC50: 2.1 nM). FGFR4-IN-11 significantly inhibits the FGF19/FGFR4 signaling pathway and exhibits anticancer effects.

FGFR4-IN-8 (Compound 7v) is an ATP-competitive inhibitor that covalently and highly selectively targets both the wild-type and gatekeeper mutant forms of FGFR4. It shows excellent inhibitory potency with IC50s of 0.5 nM for FGFR4, 0.25 nM for FGFR4 V550L, 1.6 nM for FGFR4 V550M, and 931 nM for FGFR4 C552S. Additionally, FGFR4-IN-8 has a potent antiproliferative effect on Hep3B hepatocellular carcinoma cells, with an IC50 of 29 nM, and demonstrates moderate antitumor efficacy in vivo in a Huh-7 xenograft model in nude mice [1].

FGFR4-IN-6 is a covalent, reversible FGFR4 inhibitor (IC50: 5.4 nM) that exhibits good oral pharmacokinetic properties. In a xenograft mouse model of the Hep3B2.1-7 HCC cell line, FGFR4-IN-6 was able to significantly induce tumour regression without significant toxicity.

Erdafitinib (JNJ-42756493) is a quinoxaline derivative compound, acts on FGFR1/2/3/4.

FIIN-4 is a covalent inhibitor of FGFR and can be used in studies about metastatic breast cancer.

Ferulic acid sodium (Sodium ferulic), the sodium salt of ferulic acid, is a drug used in traditional Chinese medicine for treatment of cardiovascular and cerebrovascular diseases and to prevent thrombosis.

FIIN-2, an irreversible, pan-FGFR inhibitor, inhibits FGFR1/2/3/4 with IC50 of 3.09 nM, 4.3 nM, 27 nM and 45.3 nM, respectively.

FGFR-IN-8 is a potent, orally active FGFR inhibitor that inhibits both wild-type and mutant FGFR. FGFR-IN-8 acts on FGFR1 (IC50<0.5 nM), V564F-FGFR2 (IC5016: 189.1 nM), N549H-FGFR2 (IC50<0.5 nM), V555M-FGFR3 (IC50: 22.6 nM), FGFR3 (IC50<0.5 nM) and FGFR 4 (IC50: 7.30 nM), V555M-FGFR3 (IC50: 22.6 nM), FGFR3 (IC50<0.5 nM) and FGFR 4 (IC50: 7.30 nM). FGFR-IN-8 induces apoptosis and exhibits anti-cancer effects.

FGFR4-IN-4 is a FGFR4 inhibitor with anti-tumor activity.

Nintedanib-13C-d3 is the 13C and deuterated compound of Nintedanib. Nintedanib has a CAS number of 656247-17-5. Nintedanib is an inhibitor of the receptor tyrosine kinases VEGFR/FGFR/PDGFR (IC50s: 13-34/37-610/59/65 nM for VEGFR1-3, FGFR1-4, and PDGFRα/β, respectively).

ASP5878 potently inhibited the tyrosine kinase activities of recombinant FGFR1, 2, 3, and 4 with IC50 values of 0.47, 0.60, 0.74, and 3.5 nmol/L.

Nintedanib-d8 is a deuterated compound of Nintedanib. Nintedanib has a CAS number of 656247-17-5. Nintedanib is an inhibitor of the receptor tyrosine kinases VEGFR/FGFR/PDGFR (IC50s: 13-34/37-610/59/65 nM for VEGFR1-3, FGFR1-4, and PDGFRα/β, respectively).

(E)-Ferulic acid ((E)-Coniferic acid) causes the phosphorylation of β-catenin, resulting in proteasomal degradation of β-catenin and increases the expression of pro-apoptotic factor Bax and decreases the expression of pro-survival factor survivin.t(E)-Ferulic acid exert both anti-proliferation and anti-migration effects in the human lung cancer cell line H1299.

Ferulic Acid (Coniferic acid) is a highly abundant phenolic phytochemical and a type of organic compound found in the Ferula assafoetida L. or Ligusticum chuanxiong.It can be absorbed by the small intestine and excreted through the urine.